- Home
- CYCC vs LGVN Comparison
CYCC vs LGVN Comparison
Compare CYCC & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- LGVN
- Stock Information
- Founded
- CYCC 1992
- LGVN 2014
- Country
- CYCC Malaysia
- LGVN United States
- Employees
- CYCC N/A
- LGVN N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CYCC Health Care
- LGVN Health Care
- Exchange
- CYCC Nasdaq
- LGVN Nasdaq
- Market Cap
- CYCC 17.5M
- LGVN 16.6M
- IPO Year
- CYCC N/A
- LGVN 2021
- Fundamental
- Price
- CYCC $6.37
- LGVN $0.79
- Analyst Decision
- CYCC
- LGVN Strong Buy
- Analyst Count
- CYCC 0
- LGVN 2
- Target Price
- CYCC N/A
- LGVN $6.50
- AVG Volume (30 Days)
- CYCC 82.6K
- LGVN 496.8K
- Earning Date
- CYCC 11-11-2025
- LGVN 11-11-2025
- Dividend Yield
- CYCC N/A
- LGVN N/A
- EPS Growth
- CYCC N/A
- LGVN N/A
- EPS
- CYCC N/A
- LGVN N/A
- Revenue
- CYCC $10,000.00
- LGVN $2,073,000.00
- Revenue This Year
- CYCC $137.21
- LGVN N/A
- Revenue Next Year
- CYCC N/A
- LGVN N/A
- P/E Ratio
- CYCC N/A
- LGVN N/A
- Revenue Growth
- CYCC N/A
- LGVN 68.67
- 52 Week Low
- CYCC $3.08
- LGVN $0.63
- 52 Week High
- CYCC $597.60
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- CYCC 37.28
- LGVN 37.95
- Support Level
- CYCC $5.92
- LGVN $0.78
- Resistance Level
- CYCC $8.82
- LGVN $0.85
- Average True Range (ATR)
- CYCC 0.58
- LGVN 0.05
- MACD
- CYCC -0.04
- LGVN 0.02
- Stochastic Oscillator
- CYCC 15.52
- LGVN 46.30
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.